Abstract:The inhibitory effect of erianin extracted from Dendrobium officinale on the growth of human esophageal cancer KYSE-150 cells was investigated. The CCK-8 kit, microscope, scratch test, and flow cytometry were used to determine the inhibitory effect, morphological changes, cell migration, cell apoptosis, and cycle arrest of erianin on the activity of KYSE-150 cells. Western blot analysis was used to detect the expression levels of Bax, Bcl-2, Vimentin, Akt, P-Akt, PI3K, P-PI3K, N-cadherin, and E-cadherin proteins. The results of cell experiments showed that the IC50 of erianin for inhibiting the growth of KYSE-150 cells at 24, 48, and 72 h was 357.30, 120.20, and 57.43 nmol/L, respectively. The cells exhibited reduced migration capability and demonstrated shrinkage and aggregation during growth. After treatment with 40, 80, and 120 nmol/L for 24 h, the percentage of apoptosis was found to be 27.57%, 35.38%, and 61.97%, respectively, compared with the control group. The proportion of cells in the G1 phase in the treatment group significantly decreased from 56.64 % to 2.80%, whereas the proportion of cells in the G2 phase significantly increased from 16.82% to 86.98%. The western blot results showed that the expression of Bax and E-cadherin increased, whereas the expression of Bcl-2, Vimentin, P-Akt, PI3K, P-PI3K, and N-cadherin decreased, indicating that erianin has the potential to induce apoptosis and inhibit cell migration. In summary, erianin from D. officinale has the capability to inhibit cell migration through the inhibition of the EMT pathway and KYSE-150 cell proliferation and induce apoptosis via regulation of the PI3K/Akt signaling pathway.
